Daniel Adelman

About Daniel Adelman

Daniel Adelman, M.D., was appointed Acting Chief Medical Officer of Jasper Therapeutics effective August 1, 2025, following the departure of the prior CMO during a corporate reorganization to focus resources on briquilimab in chronic urticaria . He is an experienced clinical development executive, previously serving as CMO at Aimmune Therapeutics, Alvine Pharmaceuticals, and Sunesis Pharmaceuticals; VP of Clinical Operations and Biometrics at Pharmacyclics; and Clinical Scientist at Genentech, where he was involved in the early development of omalizumab and bevacizumab . Dr. Adelman holds a B.A. in biology from the University of California, Berkeley, and an M.D. from the University of California, Davis, and has served on editorial boards of the Journal of Clinical Immunology and Clinical Immunology and as a clinical advisor to multiple biopharmaceutical companies . As Interim CMO, he publicly outlined Jasper’s investigation into anomalous efficacy results in specific BEACON dosing cohorts, emphasizing ongoing redosing and enrollment plans to support dose selection for Phase 2b in CSU .

Past Roles

Organization	Role	Years	Strategic Impact
Aimmune Therapeutics	Chief Medical Officer	—	Led clinical development in allergy therapeutics
Alvine Pharmaceuticals	Chief Medical Officer	—	Advanced therapies for celiac disease
Sunesis Pharmaceuticals	Chief Medical Officer	—	Clinical leadership in oncology pipeline
Pharmacyclics	VP, Clinical Operations & Biometrics	—	Built clinical operations and biometrics capabilities
Genentech	Clinical Scientist	—	Early development contributions to omalizumab and bevacizumab
UCSF School of Medicine	Assistant Professor; Director of Clinical Allergy & Immunology	—	Academic leadership in allergy/immunology

External Roles

Organization	Role	Years	Strategic Impact
Journal of Clinical Immunology	Editorial Board Member	—	Scientific oversight and peer-review leadership
Clinical Immunology	Editorial Board Member	—	Scientific oversight and peer-review leadership
Multiple biopharma companies	Clinical Advisor	—	Advisory input on clinical strategy and development
Jasper Therapeutics	Scientific Advisory Board Member	—	Prior advisory input before Acting CMO role

Fixed Compensation

The July 9, 2025 Form 8‑K announced Dr. Adelman’s appointment as Acting Chief Medical Officer but did not disclose his base salary, bonus targets, equity grants, or other compensatory arrangements .

Performance Compensation

No disclosure in Jasper’s 2025 filings reviewed regarding Dr. Adelman’s incentive plan metrics, RSU/PSU grants, option awards, or vesting schedules as Acting CMO .

Equity Ownership & Alignment

Dr. Adelman was not listed among directors or named executive officers in the beneficial ownership table as of April 30, 2025 (pre-dating his appointment), and no subsequent ownership disclosure specific to him was identified in reviewed filings .
Company insider trading policy prohibits hedging (including puts/calls) and pledging of Jasper stock by directors, employees, and consultants, reinforcing alignment standards .
Jasper’s clawback policy (effective October 1, 2023) requires recovery of erroneously awarded incentive-based compensation from current and former executive officers upon an accounting restatement per Rule 10D‑1 .
In the September 2025 underwritten offering lock-up list (Underwriting Agreement exhibits), company executives and directors are named; Dr. Adelman is not listed among the lock-up parties in the exhibit excerpt reviewed .

Employment Terms

Appointment: Acting Chief Medical Officer effective August 1, 2025; no employment agreement or severance/change-of-control terms for Dr. Adelman were disclosed in the July 9, 2025 Form 8‑K (which focused on the prior CMO’s severance per his agreement) .
Role scope: Interim/Acting leadership of clinical development; public commentary on BEACON cohort investigation and redosing/enrollment plans to support dose selection and program continuity .

Performance & Track Record (recent signals)

As Interim CMO, Dr. Adelman stated Jasper is investigating the atypical absence of UAS7 reductions in specific BEACON dosing cohorts, redosing patients with product from a different lot, and enrolling 10–12 additional patients, with data expected late 2025 to support Phase 2b dose selection in CSU .
Jasper’s corporate update indicated no evidence of drug substance/product manufacturing or distribution issues in the anomalous cohorts, shifting focus to site-level factors; additional BEACON/OLE data and ETESIAN asthma data are expected into Q4 2025/Q1 2026 .

Governance & Shareholder Feedback (context)

Proposal (Annual Meeting 7/3/2025)	For	Against	Abstain	Broker Non-Votes
Say‑on‑Pay (NEO compensation)	8,108,299	536,022	9,718	3,360,488
Say‑on‑Pay Frequency (years)	One Year: 8,580,886	Two Years: 5,444	Three Years: 29,171	Abstain: 38,538; Broker Non‑Votes: 3,360,488

Investment Implications

Compensation transparency gap: Absence of disclosed salary/equity/vesting terms for Dr. Adelman limits pay‑for‑performance assessment and visibility into retention incentives; watch for an Item 5.02 filing or proxy updates that detail compensatory arrangements, equity mix, and performance metrics tied to clinical milestones .
Alignment safeguards: Company‑wide prohibitions on hedging/pledging and a Rule 10D‑1 clawback framework enhance alignment and downside accountability for executive incentive pay, mitigating governance risk even without individual award details for Dr. Adelman .
Execution risk/clinical catalyst path: Dr. Adelman’s oversight of BEACON anomaly investigation, redosing, and cohort enrollment is central to dose selection and Phase 2b timing—near‑term data readouts are key trading catalysts and execution tests under his interim leadership .
Shareholder posture: 2025 say‑on‑pay passed with an annual frequency, indicating investors expect ongoing, regular scrutiny of compensation alignment—a potential catalyst for disclosure of interim executive arrangements if continued in 2026 proxy materials .